FDA approves new Alzheimer’s drug that moderately slows disease
An experimental Alzheimer’s drug that moderately slows cognitive decline was approved by the Food and Drug Administration (FDA) on Friday. The drug, called lecanemab, was granted conditional approval based on...
![What Marketers Need to Know [+ Examples]](https://www.hubspot.com/hubfs/UNGated%20Content.png)
